Key result
Tenckhoff catheter implantation is linked to ~47% lower frusemide requirements in right heart failure.
Why the study?
Progressive renal insufficiency and diuretic resistance in advanced heart failure with intractable ascites due to right heart failure present significant management challenges with limited clinical experience in peritoneal dialytic ultra-filtration.
Does Tenckhoff catheter implantation improve clinical parameters and reduce hospital admissions in patients with right heart failure and intractable ascites?
Case Report (n=6)
No
Does Tenckhoff catheter implantation improve clinical parameters and reduce hospital admissions in patients with right heart failure and intractable ascites?
Tenckhoff catheter implantation may be an effective therapeutic modality for reducing hospitalizations and diuretic requirements in patients with right heart failure and intractable ascites.
Answers are grounded in this paper and cite their sources.
May support modified peritoneal dialysis in diuretic-resistant HF with ascites; hypothesis-generating and requires prospective validation.
Tenckhoff catheter implantation and modified peritoneal dialysis as a novel therapeutic approach in diuretic resistant congestive heart failure: a single-centre case-series.Background: Progressive renal insufficiency and diuretic resistance represent significant challenges in the management of advanced heart failure, particularly in the context of intractable ascites due to Right Heart Failure (RHF). There is growing interest in the potential use of intermittent paracentesis and peritoneal dialytic ultra-filtration in this setting but clinical experience is limited.Methods: We undertook retrospective analysis of changes in the following clinical parameters in six patients (66% males, average age 53 years) who underwent Tenckhoff catheter implantation (TCI) for the management of RHF-related intractable ascites i) body weight; ii) number of heart failure related admissions and time spent in hospital; and iii) diuretic requirements. Student t-test was performed to analyse statistical significance.Results: Follow-up ranged from 4 to 16 weeks post TCI. Compared to immediately prior to TCI: i) 83% (5/6) of patients experienced an improvement in renal function; ii) average weight fell from 72.2 + 4.7 to 67.7 + 3.9 kg (mean + SEM, p = 0.054); iii) none of the patients have required heart failure related admission compared to an average number of 40 days in hospital over 6.7 admissions in the twelve months preceding TCI and iv) frusemide dose decreased from 263 + 49 to 140 + 50 mg/day, p = 0.051). All patients report a subjective improvement in overall wellbeing and quality of life. One patient developed peritonitis which was controlled with antibiotic treatment without needing catheter removal.Conclusion: Our experience supports the use of TCI as a therapeutic modality in patients with RHF and intractable ascites resistant to medical management.
No takes yet. Share an insight, caveat, or question.
Chris M. Anthony (2016) conducted a case report in Right Heart Failure with intractable ascites (n=6). Tenckhoff catheter implantation vs. Pre-implantation baseline was evaluated on Changes in body weight, heart failure related admissions, and diuretic requirements. Tenckhoff catheter implantation reduced average weight from 72.2 kg to 67.7 kg (p=0.054) and decreased frusemide dose from 263 mg/day to 140 mg/day (p=0.051) in right heart failure patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: